Allergic Rhinitis: Controlling the Burden of Disease e-Newsletter

Release date: October 23, 2013
Expiration date: October 23, 2014
Estimated time to complete activity: 1.0 hour


Rohit K. Katial, MD
Program Director
Allergy and Immunology
Professor of Medicine
Department of Medicine
National Jewish Health
Denver, Colorado

Program Overview

Recognition and adequate treatment of allergic rhinitis (AR) is an ongoing clinical challenge in the United States. Patients with AR suffer a great health burden in terms of symptoms and subsequent impact on quality of life (QOL). The presence of residual AR symptoms, dissatisfaction with current therapies, therapy failures, and costs to the healthcare system have become issues at the forefront of AR care after the recent release of several national surveys. Patient dissatisfaction with prescription nasal medications is particularly important, as some healthcare professionals may overestimate patient satisfaction with therapy. This program has been designed to address practical issues in the care of patients with AR related to recognition, diagnosis, and management of the disease.

Target Audience

This activity has been designed to meet the educational needs of allergists, otolaryngologists, otolaryngic allergists, pediatricians, primary care physicians, and other healthcare professionals involved in the care of patients with AR.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe strategies to recognize the burden of AR symptoms and their effect on a patient’s QOL
  • Describe common reasons for patient noncompliance with treatment regimens
  • Develop treatment plans that incorporate an evidence-based approach to improve adherence and outcomes for patients with AR
  • Incorporate nonpharmacologic strategies into the management of patients with AR to optimize treatment effectiveness

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Jewish Health

For questions about the accreditation of this activity, please contact National Jewish Health at 800-844-2305 or visit

Disclosure of Conflicts of Interest

All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (eg, stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. For the purposes of CME accreditation National Jewish Health considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

All CME Educational Activities sponsored by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation by our faculty CME committee. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Sean Gregory, PhD, hereby states that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the last 12 months.

Rohit K. Katial, MD
Advisory Board: Sunovion, Teva

Harold Nelson, MD
Consultant: Merck, Pearl, Shionogi
Investigator: Circassia, Lincoln Diagnostics, Rigel

Directions to the Learner

There are no fees for participating and receiving CME credit for this activity. During the period of October 23, 2013, through October 23, 2014, participants must:

  • Read the learning objectives and faculty disclosure
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 70% or better and evaluation form. Your statement of credit will be e-mailed to you within 4 weeks.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)



Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Jewish Health, Integrity Continuing Education, Inc., and TEVA Respiratory do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of National Jewish Health, Integrity Continuing Education, Inc., and TEVA Respiratory. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgement of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest


Co-sponsored by: NJH new and  integrity      Supported by an educational grant from: TR 2